Category Archives: Mesenchymal Stem Cells

In computer-based text processing and digital typesetting, a non-breaking space, no-break space or non-breakable space (NBSP) is a variant of the space character that prevents an automatic line break (line wrap) at its position. In certain formats (such as HTML), it also prevents the collapsing of multiple consecutive whitespace characters into a single space. The non-breaking space is also known as a hard space or fixed space. In Unicode, it is encoded at U+00A0 no-break space (HTML:    ). Text-processing software typically assumes that an automatic line break may be inserted anywhere a space character occurs; a non-breaking space prevents this from happening (provided the software recognizes the character). For example, if the text 100 km will not quite fit at the end of a line, the software may insert a line break between 100 and km. To avoid this undesirable behaviour, the editor may choose to use a non-breaking space between 100 and km. This guarantees that the text 100km will not be broken: if it does not fit at the end of a line it is moved in its entirety to the next line. A second common application of non-breaking spaces is in plain text file formats such … Continue reading →

On Friday the BBC broadcast a moving report about a young girl named Sohana Collins, who suffers from the painful and life threatening genetic disorder epidermolysis bullosa (EB), caused by mutations in the type VII collagen gene (Col7a1). The report also included an interview with Prof John McGrath, Professor of Molecular dermatology at Kings College London, who is leading a clinical trial EBSTEM of mesenchymal stem cell therapy for EB that Sohana is part of, who spoke about the potential for this therapy to help people with EB. Sohana Collins, who is participating in the EBSTEM trial. Image: BBC News Type VII collagen (col7) is a key component of the basement membrane of the skin, a layer of protein structures that acts as a kind of cement that binds the outermost layer of the skin the epidermis to the underlying dermal layer, and lack of clo7 leads to the two layers to move independently of each other. This shearing movement at the dermal-epidermal junction hasthe result that even the slightest injury can lead to blisters and sores, and people with EB have a very high risk of developing skin cancers. The EBSTEMtrial seeks to determine if infused mesenchymal stem cells … Continue reading →

Overview: What Are Stem Cell Treatments for Chronic Bronchitis? Stem cell treatments for chronic bronchitis are one of the latest advancements in chronic bronchitis treatments available today, and are being utilized in clinical settings around the world. Once considered an alternative form of treatment for chronic bronchitis and other forms of lung disease, stem cell therapies for chronic bronchitis are becoming increasingly more common as they provide consistent positive results for patients suffering from mild, moderate, and severe forms of chronic bronchitis. Stem cells and other forms of regenerative medicine are helping people improve their quality of life and breathe easier. Adipose (Fat-Derived) Stem Cell Procedure & Venous (Blood-Derived) Stem Cell Procedure for Chronic Bronchitis Lung Institute utilizes adult autologous stem cells, derived from the patients own body, for the adipose (fat-derived) stem cell procedure and the venous (blood-derived) stem cell procedure. These stem cells are extracted, isolated, and immediately reintroduced to the affected lung tissue, where they then divide and replicate into healthy cells specialized to that tissue. The use of autologous stem cells in transplantation is considered to be more reliable than stem cells from another individual as there is a much lower probability of rejection. Both adipose … Continue reading →

by Neil Riordan, P.A., Ph.D. Neil Riordan, P.A., Ph.D. There are four different types of lupus erythematosus, a group of diseases commonly referred to simply as "lupus." Systemic lupus erythematosus(SLE) is the most common and serious form. Professor Lingyun Sun and his colleagues have written five key articles about the treatment of Systemic Lupus Erythematosus (Lupus) with mesenchymal stem cells. I had the pleasure of meeting Professor Sun on a trip to China in 2010. Dr. Sun is at Nanjing University Medical School, in Nanjing, China. The first of the series1, published in 2009, firstly described benefits of mesenchymal stem cells (MSCs) in a mouse Lupus model. From the positive outcomes they saw in that model, they then went to humans and treated a series of 4 people who were not responding to treatment with cyclophosphamide and steroids for more than six months. Both the mice and humans were treated with donor bone marrow mesenchymal cells that were grown in the laboratory. The lupus patients received a single intravenous (IV) infusion of 1 million cells per kilogram of body weight. For an average sized person the dose would have been 70 million cells. The patients were tapered off of their … Continue reading →

Home > Stem Cell Therapy > Mesenchymal Stem Cells Call us for more information 561-320-1256 Image credit to Robert M. Hunt Mesenchymal stem cells, or MSCs for short, are multipotent stem cells that can differentiate themselves into a number of different cells including osteoblasts, chondrocytes and myocytes. More recent discoveries have indicated that MSCs can also differentiate into beta-pancreatic islets cells. MSCs can be shown in vitro and in vivo as well as ex vivo, which means that they can be cultivated and shown outside of a host organism. MSCs are found in bone marrow, although they are relatively rare and represent only around one in 10,000 nucleated cells. They are not immortal, but they are capable of expanding in cultures while maintaining their multilineage potential. These properties along with their versatility make them invaluable to stem cell treatment and stem cell therapy. Perhaps the most promising characteristic of MSCs is their potential to be used in tissue engineering. Preliminary experiments on lab animals have shown that the cells can migrate to injury sites when they are transplanted systematically, although the method of this migration remains unclear. The chemokine receptors and adhesion molecules of the stem cells allow them to … Continue reading →

Autism treatment with stem cells Stem cell therapy for autism treatment in UCTC. Professor Smikodub introduced the method of fetal stem cell therapy on the basis of which autism treatment wa... By: TheCellTreatment … Continue reading →

November 24, 2013 19:16 | Source: Mesoblast NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world's second-largest mature healthcare market. Japan's parliament, the Diet, enacted a Bill last week which revised the existing Pharmaceutical Affairs Law to define new medical products which contain stem cells to be termed regenerative medicine products. The Bill allows the Japanese Government to give conditional approval to such products if their safety is confirmed in clinical trials, as may occur on completion of Phase 2. Chief Executive Silviu Itescu discussed how the new legislation in Japan could positively impact the Company, during an interview with Inside Business on ABC-TV yesterday. To view the interview, please visit: http://www.abc.net.au/insidebusiness/ As a result of the new legislation, a pathway now exists in Japan for Mesoblast to commercialize its mesenchymal lineage stem and precursor cell products within a significantly shorter timeframe. Mesoblast intends to establish strategic partnerships for its suite of products to facilitate earlier Japanese regulatory approvals and commercial launches. Mesoblast's first strategic partnership in … Continue reading →

http://www.CLINICell.com "ACL TEAR alternative with PRP and Stem Cell Therapy" http://www.CLINICell.com offers the latest alternative treatments with PRP and Stem Cell Therapy for an ACL Tear. Platelet Rich Plasma and Stem Cell treatments can ... By: ClinicellTech … Continue reading →

Objective: Recent evidence suggests that mesenchymal stem cells may attenuate lung inflammation and fibrosis in acute lung injury. However, so far, no study has investigated the effects of mesenchymal stem cell therapy on the time course of the structural, mechanical, and remodeling properties in pulmonary or extrapulmonary acute lung injury. Design: Prospective randomized controlled experimental study. Setting: University research laboratory. Subjects: One hundred forty-three females and 24 male C57BL/6 mice. Interventions: Control mice received saline solution intratracheally (0.05 mL, pulmonary control) or intraperitoneally (0.5 mL, extrapulmonary control). Acute lung injury mice received Escherichia coli lipopolysaccharide intratracheally (2 mg/kg in 0.05 mL of saline/mouse, pulmonary acute lung injury) or intraperitoneally (20 mg/kg in 0.5 mL of saline/mouse, extrapulmonary acute lung injury). Mesenchymal stem cells were intravenously injected (IV, 1 105 cells in 0.05 mL of saline/mouse) 1 day after lipopolysaccharide administration. Measurements and Main Results: At days 1, 2, and 7, static lung elastance and the amount of alveolar collapse were similar in pulmonary and extrapulmonary acute lung injury groups. Inflammation was markedly increased at day 2 in both acute lung injury groups as evidenced by neutrophil infiltration and levels of cytokines in bronchoalveolar lavage fluid and lung tissue. Conversely, collagen … Continue reading →

Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohns disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell populations phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing … Continue reading →